CRANFORD, N.J., Sept. 13, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away on Monday. Mr. Safir joined the Citius Board of Directors in 2014, providing invaluable counsel to the Citius management team for nearly a decade.
“We are deeply saddened to announce the passing of our friend and longtime board member, Howard Safir. Howard was an outstanding and admirable leader whose insights helped shape the growth of Citius for almost ten years. We are honored to have worked alongside Howard on the Citius board and grateful for his thoughtful guidance, wisdom, and friendship,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals. “On behalf of our entire organization and Board of Directors, we wish to extend our deepest condolences and sympathies to Howard’s family and friends. May his legacy be an enduring commitment to positively impacting society.”
Throughout his distinguished career, Howard Safir’s dedication to public service was an inspiration to many. Prior to joining the Citius Board of Directors in 2014, Howard served as Chairman and Chief Executive Officer multiple security consulting firms following his tenures as the 39th Police Commissioner of the City of New York, Associate Director for Operations of the US Marshals Service, and Assistant Director of the Drug Enforcement Administration. In addition to his role as the Lead Independent Director at Citius, he served on the boards of several life science and technology companies. He will be greatly missed by the Citius family.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company’s diversified pipeline includes two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in CTCL. Mino-Lok was granted Fast Track designation by the FDA. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. At the end of March 2023, Citius completed enrollment in its Phase 2b trial of CITI-002, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
[email protected]
908-967-6677 x113
SOURCE Citius Pharmaceuticals, Inc.
